Simple Vitamin Solves Cancer Therapy's Anemia Problem

Cancer patients struggling with severe anemia during treatment may finally have a solution hiding in plain sight: an inexpensive vitamin supplement.

Researchers at Mount Sinai's Tisch Cancer Center just overturned a long-held assumption about PARP inhibitors, a widely used cancer drug for ovarian, breast, prostate, and pancreatic cancers. For years, doctors believed the debilitating anemia these drugs caused was simply an unavoidable side effect of how the medication works.

They were wrong.

The team discovered that many patients actually develop severe folate deficiency while taking PARP inhibitors. This deficiency, easily spotted with a basic blood test and treated with folic acid pills, was causing the crippling fatigue, shortness of breath, and dizziness that forced patients to pause their cancer treatment.

Dr. Noa Rippel and her team reviewed records from 512 patients taking PARP inhibitors. They found folate deficiency anemia in 3.1 percent of patients, more than six times the rate in the general population. Another 30 percent showed warning signs that likely went undiagnosed.

The numbers tell a sobering story about what patients endured. More than 60 percent of those with folate deficiency needed blood transfusions. Three out of four had to interrupt their cancer therapy, the very treatment keeping them alive.

The Bright Side

The encouraging news? Every patient who received folic acid supplements recovered their folate levels and their anemia improved. They could safely resume the cancer treatment that was extending their lives.

Even better, the research suggests starting folic acid when patients begin PARP inhibitor therapy might prevent the problem entirely. The solution costs pennies per day and requires no complex medical procedures.

Published in Blood Red Cells & Iron journal, this study marks the first time researchers systematically examined folate deficiency in PARP inhibitor patients. Previous reports existed only as isolated cases, easy for busy oncologists to overlook.

As PARP inhibitors gain approval for treating more cancer types, this discovery could help thousands of patients annually. The researchers hope their findings will reshape clinical guidelines and make routine folate monitoring standard practice during treatment.

What makes this breakthrough particularly meaningful is its simplicity. No expensive new drugs needed. No complicated procedures required. Just awareness, a basic blood test, and a vitamin that's been around for decades.

For cancer patients and their families, this represents something precious: fewer treatment interruptions, less time in hospitals, and more energy to focus on healing rather than managing side effects.

A simple vitamin is keeping people on the therapy that could save their lives.